Juvaris BioTherapeutics Inc., a private biotechnology company, has stepped into a research collaboration with the International AIDS Vaccine Initiative (IAVI) to use Juvaris' immunostimulant technology in the screening of Human Immunodeficiency Virus (HIV) vaccine candidates.

The research collaboration will consist of testing the JuvImmune / JuvaVax Immunostimulant combined with HIV antigens. Studies will be conducted in an HIV immunization model through IAVI's affiliated network of scientific investigators and laboratories. IAVI's mission is to ensure the development of a safe, effective and accessible vaccine to prevent HIV infection and AIDS.

In commenting on the IAVI collaboration, Juvaris' CEO Martin D. Cleary stated, "Juvaris is excited to collaborate with IAVI in the screening of HIV vaccine candidates using the Company's Immunostimulant/Vaccine technology platform. We believe the various attributes of the Juvaris vaccine platform strongly support IAVI's vaccine efforts. Our preclinical testing has demonstrated potent cellular and antibody-mediated immune stimulation as well as the efficacy of oral administration. Juvaris appreciates the opportunity to demonstrate the power of its immunostimulation technology through the IAVI collaboration."